GV and Novo-backed cardiovascular disease drug developer Verve priced an upscaled initial public offering above its range.
US-based cardiovascular disease therapy developer Verve Therapeutics is going public today in a $267m initial public offering representing exits for internet and technology group Alphabet and pharmaceutical firm Novo.
The offering consists of just over 14 million shares issued on the Nasdaq Global Select Market, increased from 11.8 million and priced at $19.00 each, above the $16 to $18 range set for the offering. The IPO price values the company at approximately $876m.
Verve is working on gene therapies to…
